SurmodicsSRDX
SRDX
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
95% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $681K
15% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 39
10% more funds holding
Funds holding: 126 [Q3] → 138 (+12) [Q4]
1.09% more ownership
Funds ownership: 83.17% [Q3] → 84.26% (+1.09%) [Q4]
4% more capital invested
Capital invested by funds: $457M [Q3] → $476M (+$19.2M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$43
50%
upside
Avg. target
$43
50%
upside
High target
$43
50%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Brooks O'Neil 25% 1-year accuracy 4 / 16 met price target | 50%upside $43 | Buy Upgraded | 7 Mar 2025 |
Financial journalist opinion
Based on 3 articles about SRDX published over the past 30 days
Neutral
Business Wire
1 day ago
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil™ drug-coated balloon (DCB) is non-inferior to the IN.PACT™ Admiral™ DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were.
Neutral
Zacks Investment Research
2 weeks ago
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System
Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions.
Neutral
Business Wire
2 weeks ago
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commercial release of the Pounce™ XL Thrombectomy System, the latest in a suite of Pounce Thrombectomy systems that provide rapid endovascular removal of acute or chronic clot from peripheral arteries. Intended for removal of thrombi and emboli from peripheral arteries ranging from 5.5–10 mm in diameter,.
Positive
Zacks Investment Research
1 month ago
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now
SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.
Negative
Zacks Investment Research
1 month ago
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.
Neutral
Business Wire
1 month ago
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following statement in response to the U.S. Federal Trade Commission's (“FTC” or the “Agency”) announcement that it will challenge the proposed acquisition of Surmodics (the “Merger”) by funds affiliated with GTCR LLC (“GTCR”), which have an equity investment in Biocoat Inc., a maker of medical coatings: “Surmodics.
Negative
Reuters
1 month ago
FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics
The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' acquisition by private equity firm GTCR, with the regulatory agency alleging the deal was anticompetitive.
Positive
Benzinga
2 months ago
Top 3 Health Care Stocks You'll Regret Missing This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Positive
Zacks Investment Research
2 months ago
SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
Business Wire
2 months ago
Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful early clinical use of its Pounce™ XL Thrombectomy System. The Pounce XL Thrombectomy System received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2024, and is currently in limited market release (LMR), with full commercial launch planned following completion of the LMR.
Charts implemented using Lightweight Charts™